Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
$1.41
-7.2%
$1.66
$1.14
$42.40
$3.95M-2.99521,395 shs127,712 shs
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$0.98
+3.1%
$0.93
$0.64
$1.58
$37.16M-0.835,532 shs16,172 shs
MDxHealth SA stock logo
MDXH
MDxHealth
$2.19
-0.9%
$2.02
$1.35
$3.50
$103.56M1.3190,422 shs21,561 shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$15.84
+2.2%
$15.38
$10.91
$40.26
$949.95M2.68579,895 shs506,667 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
0.00%-29.85%+2.17%-14.29%-89.01%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
0.00%+4.84%-1.52%+42.96%-31.82%
MDxHealth SA stock logo
MDXH
MDxHealth
0.00%-4.78%+5.29%+47.97%-6.01%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
0.00%+4.07%-4.69%+23.85%-38.51%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
3.0533 of 5 stars
3.52.00.00.03.01.71.3
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
2.8083 of 5 stars
3.55.00.00.00.00.81.3
MDxHealth SA stock logo
MDXH
MDxHealth
1.5969 of 5 stars
3.53.00.00.00.00.00.6
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
1.5637 of 5 stars
3.60.00.00.00.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
3.00
Buy$16.501,070.21% Upside
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
3.00
Buy$6.25541.03% Upside
MDxHealth SA stock logo
MDXH
MDxHealth
3.00
Buy$6.50196.80% Upside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
3.25
Buy$53.40237.12% Upside

Current Analyst Ratings Breakdown

Latest AMIX, BRNS, SYRE, and MDXH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$65.00
4/29/2025
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
4/8/2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/8/2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$45.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
N/AN/AN/AN/A$3.29 per shareN/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
$14.97M2.63N/AN/A$3.23 per share0.30
MDxHealth SA stock logo
MDXH
MDxHealth
$90.05M1.15N/AN/A$0.31 per share7.06
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K1,072.85N/AN/A$7.04 per share2.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
-$11.41M-$7.47N/AN/AN/AN/A-174.70%-133.35%N/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$61.07M-$1.64N/AN/AN/AN/A-46.43%-38.50%8/6/2025 (Estimated)
MDxHealth SA stock logo
MDXH
MDxHealth
-$38.07M-$1.15N/AN/AN/A-41.02%-492.11%-23.00%8/20/2025 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$208.02M-$3.77N/AN/AN/AN/A-77.46%-41.06%8/6/2025 (Estimated)

Latest AMIX, BRNS, SYRE, and MDXH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2025
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
N/A-$0.74N/A-$0.74N/AN/A
5/14/2025Q1 2025
MDxHealth SA stock logo
MDXH
MDxHealth
-$0.13-$0.19-$0.06-$0.19$22.62 million$24.29 million
5/8/2025Q1 2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.76-$0.74+$0.02-$0.74N/AN/A
5/7/2025Q1 2025
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
-$0.34-$0.49-$0.15-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
N/AN/AN/AN/AN/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/AN/AN/AN/AN/A
MDxHealth SA stock logo
MDXH
MDxHealth
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
N/A
5.63
5.63
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
N/A
9.18
9.18
MDxHealth SA stock logo
MDXH
MDxHealth
13.81
2.00
1.92
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
8.06
8.06

Institutional Ownership

CompanyInstitutional Ownership
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
10.78%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
25.20%
MDxHealth SA stock logo
MDXH
MDxHealth
N/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%

Insider Ownership

CompanyInsider Ownership
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
32.40%
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
10.70%
MDxHealth SA stock logo
MDXH
MDxHealth
1.70%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.43%
CompanyEmployeesShares OutstandingFree FloatOptionable
Autonomix Medical, Inc. stock logo
AMIX
Autonomix Medical
12.78 million1.88 millionN/A
Barinthus Biotherapeutics PLC Sponsored ADR stock logo
BRNS
Barinthus Biotherapeutics
10740.34 million36.02 millionN/A
MDxHealth SA stock logo
MDXH
MDxHealth
30047.29 million46.48 millionNot Optionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
7360.28 million50.98 millionOptionable

Recent News About These Companies

SYRE - Spyre Therapeutics Inc Trailing Returns - Morningstar
Spyre Therapeutics Announces Grants of Inducement Awards

New MarketBeat Followers Over Time

Media Sentiment Over Time

Autonomix Medical stock logo

Autonomix Medical NASDAQ:AMIX

$1.41 -0.11 (-7.24%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$1.43 +0.02 (+1.42%)
As of 07/3/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

Barinthus Biotherapeutics stock logo

Barinthus Biotherapeutics NASDAQ:BRNS

$0.98 +0.03 (+3.07%)
Closing price 07/3/2025 01:46 PM Eastern
Extended Trading
$0.98 0.00 (0.00%)
As of 07/3/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

MDxHealth stock logo

MDxHealth NASDAQ:MDXH

$2.19 -0.02 (-0.90%)
As of 07/3/2025 01:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$15.84 +0.34 (+2.19%)
As of 07/3/2025 02:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.